Charles River Laboratories (CRL) Tops Q4 EPS by 15c
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $288.50 --0%
Revenue Growth %: -4.3%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.40, $0.15 better than the analyst estimate of $1.25. Revenue for the quarter came in at $478.5 million versus the consensus estimate of $474.59 million.
GUIDANCE:
Charles River Laboratories sees FY2018 EPS of $5.42-$5.57, versus the consensus of $5.58.
- Revenue growth, reported 7.2% - 8.2%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- Solaris Energy raises 2026 guidance, initiates Q1 2027 outlook
- HSBC explains why risk assets continue to ignore every negative catalyst
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
